Fulcrum Therapeutics Inc (FULC) Stock Price Quote Today & Current Price Chart
This page provides current stock price quotes and chart information for Fulcrum Therapeutics Inc (FULC), a clinical-stage biopharmaceutical company. It details FULC's medical focus on genetically defined diseases, including its lead product candidates losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease and β-thalassemia. The article also includes trading conditions for CFDs, key financial statistics, and recent related market news.
Vanguard entities disaggregate Fulcrum holdings (FULC) after internal realignment
The Vanguard Group has filed an Amendment No. 2 to a Schedule 13G/A, reporting 0 shares beneficially owned and 0% of common stock in Fulcrum Therapeutics Inc (FULC) as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, which caused certain Vanguard subsidiaries to report their beneficial ownership separately. The filing clarifies that this is a procedural change in reporting rather than an indication of market transactions or sales of shares.
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index
Fulcrum Therapeutics, Inc. (NasdaqGM:FULC) has been added to the S&P Pharmaceuticals Select Industry Index. This news follows several other recent announcements from the company, including positive results from its Phase 1b PIONEER trial for Pociredir in sickle cell disease and an analyst initiation with an "Overweight" rating. The company focuses on developing treatments for genetically defined rare diseases.
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
MedicAlert Foundation, the Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics have partnered to enhance emergency department (ED) care for individuals with sickle cell disease (SCD). This collaboration aims to expedite access to patient-specific care plans during pain crises through MedicAlert Smart Medical ID Cards, which provide critical health information to clinicians. The program seeks to address barriers to timely and compassionate care for the 100,000 people in the U.S. affected by SCD.
QR medical ID cards aim to speed ER care during sickle cell pain crises
Fulcrum Therapeutics, the MedicAlert Foundation, and the Sickle Cell Disease Association of America (SCDAA) have partnered to accelerate emergency department care for individuals with sickle cell disease (SCD). This three-year collaboration focuses on providing MedicAlert Smart Medical ID Cards, which leverage QR codes to give ER clinicians immediate access to critical patient-specific care plans, including pain management strategies, hematologist contacts, medications, and allergies. The initiative aims to reduce delays and improve the quality of care during acute pain crises for the estimated 100,000 people living with SCD in the U.S.
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
MedicAlert Foundation, the Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics have partnered to streamline emergency department care for individuals with sickle cell disease (SCD). This three-year collaboration aims to provide rapid access to patient-specific care plans via a MedicAlert Smart Medical ID Card, helping clinicians deliver timely and targeted care during pain crises. The initiative seeks to address barriers to appropriate care and improve care coordination for the 100,000 people affected by SCD in the U.S.
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7%
Short interest in Fulcrum Therapeutics (NASDAQ:FULC) rose by 19.7% in February, reaching 4,210,945 shares. This represents 6.8% of the company's shares sold short, with a short-interest ratio of 3.8 days. Insiders own 7% of the stock, while institutional investors hold nearly 90%, including recent increases from major firms.
Boothbay Fund Management Increases Stake in Fulcrum Therapeutics
Boothbay Fund Management LLC significantly increased its stake in Fulcrum Therapeutics (NASDAQ:FULC) by 104.2% during the third quarter, now owning 678,414 shares. This move suggests the hedge fund sees considerable potential in the clinical-stage biotech company's pipeline and future prospects. The investment highlights confidence in Fulcrum Therapeutics' focus on developing treatments for genetic diseases.
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC
Boothbay Fund Management LLC significantly increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 104.2% in the third quarter, now owning 678,414 shares worth $6.24 million. Other hedge funds like Cubist Systematic Strategies and Jane Street Group LLC also modified their holdings, with institutional investors now owning 89.83% of the stock. Analyst ratings for FULC are mixed, with an average "Moderate Buy" rating and a target price of $19.00, while insider trading shows a director selling 15,000 shares.
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet
This article from MSN discusses Fulcrum Therapeutics (FULC) and its potential stock surge based on Wall Street analysts' price targets. Analysts project a 58.47% upside for the stock, indicating strong confidence in the company's future performance. Investors are advised to review this analysis before making any investment decisions regarding FULC.
219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP
Braidwell LP recently acquired 219,488 shares of Fulcrum Therapeutics (NASDAQ:FULC) in the third quarter, a new stake valued at approximately $2.02 million and representing 0.41% of the company. Institutional investors and hedge funds own a significant portion of the stock, while insiders like director Robert J. Gould have recently sold shares. Analysts currently have a "Moderate Buy" rating for Fulcrum Therapeutics with an average price target of $19.
Suvretta Capital Management LLC Raises Holdings in Fulcrum Therapeutics, Inc. $FULC
Suvretta Capital Management LLC increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 5.9% in the third quarter, bringing its total holdings to 5,381,000 shares valued at approximately $49.5 million. Other institutional investors also adjusted their positions in the company. Fulcrum Therapeutics, which has a market cap of about $509 million and a beta of 3.23, is rated a "Moderate Buy" by analysts with an average target price of $19.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, a biopharmaceutical company, announced it granted stock options to a new employee as an inducement for employment, as per Nasdaq Listing Rule 5635(c)(4). This grant includes 34,000 options to purchase common stock at an exercise price of $7.81 per share, vesting over four years. The company specializes in developing small molecules for genetically defined rare diseases.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Leerink Partners Global Healthcare Conference. Management will present on March 10, 2025, at 1:00 p.m. ET in Miami, FL. A webcast of the presentation will be available on the company's website, with a replay accessible for at least 30 days.
New Fulcrum hire gets 34,000 stock options with 4-year vesting
Fulcrum Therapeutics (Nasdaq: FULC) granted 34,000 non-statutory stock options to a new employee as an inducement, priced at $7.81 per share. These options have a 10-year term and vest over four years, with 25% on the first anniversary and quarterly thereafter. This grant was made under the company's 2022 Inducement Stock Incentive Plan, affecting FULC's market valuation by approximately -$16 million due to a 2.82% decline on the day of publication.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced that its management will present at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2025, at 1:00 p.m. ET. A webcast of the presentation will be available on the company's website, with a replay accessible for at least 30 days. The company focuses on developing small molecules for genetically defined rare diseases.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced that its management will participate in the Leerink Partners Global Healthcare Conference on March 10, 2025. The company will present at 1:00 p.m. ET, and a webcast of the presentation will be available on their website. Fulcrum Therapeutics focuses on developing small molecules for genetically defined rare diseases, with their lead program, pociredir, aimed at treating SCD.
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its management will present at the Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:00 p.m. ET. The presentation will be webcast and available for replay on the company's website. Fulcrum focuses on developing small molecules for genetically defined rare diseases, with its lead program being pociredir for sickle cell disease.
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5% - Here's Why
Fulcrum Therapeutics (NASDAQ:FULC) stock dropped 7.5% during Monday's mid-day trading with significantly reduced volume, closing at $7.755. Despite this decline, analysts maintain a "Moderate Buy" consensus rating with an average price target of $19.00. The stock's performance is further impacted by notable insider and major-shareholder selling, including a director and Ra Capital Management, though the company did meet EPS estimates for its recent quarterly earnings.
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings
HC Wainwright has raised its Q1 2026 earnings per share estimates for Fulcrum Therapeutics (NASDAQ:FULC) to ($0.28), maintaining a "Buy" rating and a $25.00 price target. The company recently reported Q4 2025 EPS of ($0.31), meeting analyst consensus. However, the article also highlights recent insider selling from a director and a major shareholder, alongside a "Moderate Buy" consensus rating from analysts with an average target price of $19.00.
Fulcrum Therapeutics (NASDAQ: FULC) posts wider 2025 loss and boosts cash runway
Fulcrum Therapeutics reported a significantly wider net loss of $74.9 million in 2025, compared to $9.7 million in 2024, primarily due to a lack of collaboration revenue. Despite the increased loss, the company improved its cash position to $352.3 million by the end of 2025, extending its cash runway into 2029 following a $164.2 million equity offering. Clinically, Fulcrum announced positive 12-week results from its Phase 1b PIONEER trial for pociredir in sickle cell disease, showing promising increases in fetal hemoglobin and improvements in other markers, leading to plans for a registration-enabling trial in late 2026.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript
Fulcrum Therapeutics presented Q4 2025 earnings call transcript and 12-week data from the 20-milligram cohort of its Phase 1b PIONEER trial for pociridir in sickle cell disease. The data showed rapid and robust HbF induction, with over half of patients achieving clinically meaningful levels, alongside reductions in hemolysis markers and an increase in total hemoglobin. The company plans to initiate a potential registration-enabling trial in the second half of 2026, targeting a severe patient population.
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026
H.C. Wainwright reaffirmed its Buy rating on Fulcrum Therapeutics, Inc. (FULC) on February 24, 2026, following a review of PIONEER data for pociredir, without issuing a new price target. Despite the maintained bullish stance, FULC's stock experienced a -6.92% pullback. Meyka AI currently rates FULC with a B+ grade, indicating its relative performance.
Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million.
Fulcrum Therapeutics announced that by the end of 2025, its cash, cash equivalents, and marketable securities are projected to total $352.3 million. This substantial capital base is expected to fund the company's operations until 2029, indicating strong financial stability and potential for long-term growth.
Fulcrum Therapeutics, Inc. SEC 10-K Report
Fulcrum Therapeutics, Inc. has released its 2025 Form 10-K report, highlighting a net loss of $(74.9) million due to decreased collaboration revenue after the Sanofi agreement termination. The company is focused on its lead product candidate, pociredir, for sickle cell disease, with plans for a potential registration-enabling trial in late 2026. While supported by $352.3 million in cash as of December 2025, Fulcrum faces significant financial, operational, and regulatory risks, necessitating further funding as it progresses development and commercialization efforts.
Fulcrum Therapeutics Announces Recent Business Highlights
Fulcrum Therapeutics announced positive 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial for pociredir in sickle cell disease, showing significant fetal hemoglobin induction and improvements in disease markers. The company plans to initiate a potential registration-enabling trial in the second half of 2026 and reported a strong cash position of $352.3 million, extending its cash runway into 2029. Fulcrum will focus resources on pociredir and its core benign hematology programs, discontinuing a bone marrow failure syndromes program.
Experimental sickle cell pill left most patients crisis-free for 12 weeks
Fulcrum Therapeutics announced positive 12-week results from their Phase 1b PIONEER trial of pociredir for sickle cell disease. The 20 mg dose cohort showed significant increases in fetal hemoglobin (HbF) and F-cells, improved markers of hemolysis and anemia, and a substantial reduction in vaso-occlusive crises (VOCs) for most patients. Despite the positive clinical data, the company's stock, FULC, experienced a notable decline on the day the news was published.
What's Going On With Fulcrum Therapeutics Stock Tuesday?
Fulcrum Therapeutics stock fell on Tuesday after the company released initial results from its Phase 1b PIONEER trial for pociredir in sickle cell disease. The data showed significant increases in fetal hemoglobin and improvements in markers of hemolysis and anemia, with no serious adverse events. The company plans to initiate a potential registration-enabling trial in the second half of 2026 and engage with the European Medicines Agency.
Fulcrum Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Fulcrum Therapeutics Inc (FULC) is expected to report a loss of 31 cents per share, according to an earnings preview. This information is provided by Reuters and Refinitiv.
Sickle cell trial data from Fulcrum drug set for Feb. 24
Fulcrum Therapeutics (Nasdaq: FULC) announced it will present 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease on February 24, 2026, at 8:00 a.m. ET. Management and Dr. Martin Steinberg will discuss the data, which investors can access via a live webcast with a replay available afterward. This announcement serves as an upcoming clinical catalyst for the company, and its stock previously saw a mild positive reaction to this news.
Fulcrum Therapeutics (NASDAQ:FULC) Trading 6.5% Higher - What's Next?
Fulcrum Therapeutics (NASDAQ: FULC) saw its shares climb 6.5% during mid-day trading on Thursday, reaching approximately $11.65 despite significantly lower trading volume. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $19.11, though recent insider and major-holder selling has been noted. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines through epigenetic control.
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Unpacking The 74.59% Potential Upside
Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company, presents a high-risk, high-reward investment opportunity with a 74.59% potential upside according to analysts. Despite facing early-stage biotech challenges like negative EPS and free cash flow, the company is developing promising therapies for genetically defined diseases, including pociredir for sickle cell disease. Its strong pipeline, strategic collaborations, and an oversold technical indicator (RSI) contribute to a positive investor sentiment, with an average target price of $19.10.
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday
Fulcrum Therapeutics (FULC) is scheduled to release its Q4 2025 earnings before market open on Tuesday, February 24th, with analysts projecting a loss of $0.31 per share. The company has seen significant insider selling, including a major sale by Ra Capital Management, and institutional investors hold a large portion of the stock. Analysts currently have a "Moderate Buy" consensus rating with an average target price of $19.11.
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics will host a conference call and webcast on February 24, 2026, to present 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir for sickle cell disease. Pociredir is an investigational oral small-molecule inhibitor designed to increase fetal hemoglobin, which has shown dose-dependent increases in HbF and improvements in markers of hemolysis and anemia, with general tolerability across dose cohorts. Dr. Martin Steinberg, a leading hematologist specializing in sickle cell disease, will join Fulcrum management for the presentation.
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 - DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is projected for significant growth between 2020 and 2034, driven by increasing prevalence, awareness, and the launch of pipeline products. Key companies like Avidity Biosciences and Fulcrum Therapeutics are advancing therapies, with several clinical trial milestones and funding rounds noted for 2024 and 2025. The market analysis by DelveInsight covers epidemiology, treatment trends within the 7MM (United States, EU4, UK, Japan), and highlights promising emerging therapies.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received a "Moderate Buy" consensus rating from ten analysts, with an average 12-month price target of $19.11. Despite this positive outlook, the company has seen significant insider and major-holder selling, including a 40.82% reduction by Ra Capital and approximately $58.7 million in insider sales over the last quarter. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines to modulate gene expression, with key programs targeting sickle cell disease, beta-thalassemia, and facioscapulohumeral muscular dystrophy.
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
Shares of Fulcrum Therapeutics (FULC) have seen a 4.9% gain recently, with Wall Street analysts projecting a potential upside of 75.7% based on a mean price target of $19.1. Despite the optimism, the article cautions investors that price targets can often be misleading and should be viewed with skepticism, though a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) for FULC provide stronger indications of potential upside.
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
Shares of Fulcrum Therapeutics (FULC) recently closed at $10.87, and Wall Street analysts predict a mean price target of $19.1, suggesting a potential upside of 75.7%. However, investors are cautioned that price targets can be misleading, and a low standard deviation in estimates indicates a higher agreement among analysts. The company's strong Zacks Rank #2 (Buy) and positive revisions in earnings estimates further support potential near-term upside.
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies
This report from DelveInsight offers a comprehensive overview of the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline, detailing over 10 key companies and 12+ treatment therapies in various stages of clinical development. It highlights major market players like Dyne Therapeutics, Avidity Biosciences, and Fulcrum Therapeutics, and emerging therapies such as DYNE-301, MC-DX4, and Losmapimod. The report also covers recent clinical trial advancements, funding, and regulatory progress, emphasizing the growing efforts to develop effective treatments for FSHD.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. announced it granted non-statutory stock options to one new employee under its 2022 Inducement Stock Incentive Plan. This grant, involving 70,000 options at an exercise price of $10.72, was made to induce the employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, subject to continued service.
Insider Sell: Robert Gould Sells 15,000 Shares of Fulcrum Therapeutics Inc (FULC)
Robert Gould, a Director at Fulcrum Therapeutics Inc (FULC), sold 15,000 shares of the company on February 2, 2026, reducing his total holdings to 454,864 shares. This transaction is part of a trend over the past year where Gould has sold a total of 60,000 shares with no buys, and the company has seen 7 insider sells versus 0 buys. Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, is currently considered a "Possible Value Trap, Think Twice" by GuruFocus, with a price-to-GF-Value ratio of 0.29 given its $10.72 stock price against a GF Value of $36.72.
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: An Ambitious Biotech with 92.93% Upside Potential
Fulcrum Therapeutics (FULC) is a clinical-stage biopharmaceutical company focused on genetically defined diseases, with a significant 92.93% potential upside according to analysts. Despite current negative financial metrics typical of R&D-heavy biotech firms, the company's flagship product, pociredir, and collaborations with industry giants position it for future growth. Investors should weigh the high potential rewards against the inherent volatility and uncertainty of biotechnology investments.
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC
Campbell & CO Investment Adviser LLC has initiated a new position in Fulcrum Therapeutics (NASDAQ:FULC) by acquiring 102,470 shares valued at approximately $943,000, representing 0.19% ownership. This move comes amidst significant insider selling, with Ra Capital Management notably reducing its stake by over 40% and other insiders selling around 4.2 million shares in the past 90 days. Despite insider selling, analysts maintain a "Moderate Buy" consensus with a $19.11 price target, with some firms raising targets up to $25.
Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen
Wall Street Zen downgraded Fulcrum Therapeutics (NASDAQ:FULC) from "hold" to "sell." This downgrade follows significant insider selling, including a major shareholder cutting its stake by over 40%, and the company missing its last EPS estimates. Despite these negative indicators, the stock trades around $10.14, while analysts maintain a "Moderate Buy" consensus with an average price target of $19.11.
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating
Truist Financial analyst Gregory Renza has reiterated a Buy rating on Fulcrum Therapeutics (FULC.US). The analyst's past performance shows a 50.2% success rate and an average return of 23.2% over the last year, according to TipRanks data. This information is intended for informational purposes only and does not constitute investment advice.
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts have initiated coverage on five companies, including Netflix Inc., Medline Inc., Hims & Hers Health Inc., Andersen Group Inc., and Fulcrum Therapeutics Inc. Netflix received a Buy rating with a $107 price target from HSBC. The other companies also saw new coverage with Outperform, In-Line, Overweight, and Buy ratings respectively from various banks.
JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target
JPMorgan has initiated coverage on Fulcrum Therapeutics (NASDAQ: FULC) with an "Overweight" rating and a price target of $20. The biopharmaceutical company focuses on genetically defined rare diseases and has product candidates like losmapimod for FSHD and FTX-6058 (pociredir) for sickle cell disease. This positive analyst rating comes amidst recent news including clinical trial results and stock offerings.
JP Morgan Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight Recommendation
JP Morgan has initiated coverage of Fulcrum Therapeutics (FULC) with an Overweight recommendation. Analysts project a potential 96.75% upside with an average one-year price target of $19.38/share. The article also details institutional ownership, fund sentiment, and key shareholder positions, indicating a bullish outlook for the company.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. announced it granted non-statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan. This comes as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options allow the purchase of 30,400 shares at an exercise price of $10.84 per share, vesting over four years.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics announced that it granted non-statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan. These grants, totaling 30,400 options at an exercise price of $10.84 per share, are an inducement for their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with a ten-year term, subject to continued service.
